Overview

Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC

Status:
Recruiting

Trial end date:
2025-03-01

Target enrollment:

Participant gender:

Summary

Evaluate the safety and efficacy of eftilagimod alpha in combination with pembrolizumab against pembrolizumab alone in 1st line metastatic or recurrent HNSCC with PD-L1 positive (CPS ≥1) tumors, and determine the efficacy and safety of efti plus pembrolizumab in patients with PD-L1 negative tumors.

Phase:

Phase 2

Details

Lead Sponsor:

Immutep S.A.
Immutep S.A.S.

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Pembrolizumab